All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
ALL HubGVhD HubLymphoma HubMDS HubMPN HubMultiple Myeloma

Subgroup analysis of outcomes in patients with AML-MRC who achieved remission with CPX-351 versus 7+3

Mar 17, 2020

Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is associated with poor prognosis after induction therapy. CPX-351, a liposomal combination of daunorubicin (D) plus cytarabine (C), demonstrated a significantly improved median overall survival (OS) compared to a standard 7+3 regimen in older patients (60–75 years of age) with newly diagnosed high-risk or secondary AML.1 An interview with Jeffrey E. Lancet discussing results of the trial is available here. You can also read about the impact of gene mutations on the efficacy of combination here.

Daniel H.Ryan and colleagues conducted an exploratory subgroup analysis of a phase III study (NCT01696084) comparing outcomes in patients who achieved complete remission (CR) or CR with an incomplete neutrophil/platelet recovery (CRi) across treatment groups.2 These data were presented at the Transplantation & Cellular Therapy Meeting February, 19–23, 2020, Florida, US.


  • Patients were randomized to one or two induction cycles with
    • CPX-351 – 100 units/m2 of C, 100 mg/m2 + D, 44 mg/m2 infusions on Days 1, 3, and 5 (2nd induction: Days 1 and 3)
    • 7+3 – C 100 mg/m2 daily continuously for seven days (2nd induction: 5 days) + D 60 mg/m2 on Days 1–3 (2nd induction: Days 1–2)
  • Patients in CR or CRi could receive two consolidation cycles with CPX-351 (65 units/m2 of C, 65 mg/m2 + D 29 mg/m2 on Days 1 and 3) or 5 + 2 (as in 2nd induction). Hematopoietic cell transplantation (HCT) was allowed at the physician's discretion


  • In total, 246/309 of patients (80%) were diagnosed with AML-MRC, with 123 per treatment group
  • There were more patients in CR + CRi in the CPX-351 group compared to the 7 + 3 group (48% vs 33%, respectively; odds ratio, 1.83; 95% CI, 1.09–3.09)
  • Patients with AML-MRC, who achieved CR + CRi had longer median OS with CPX-351 vs 7+3 (19.5 vs 11.58; HR, 0.58; 95% CI, 0.34–0.96)
  • OS from date of HCT was also higher in patients who received CPX-351 vs 7+3 (NR vs 14.09; HR, 0.61; 95% CI, 0.27–1.40)
  • The HCT rate in AML-MRC patients with CR + CRi was higher with CPX-351 than with 7+3 (54% vs 43%, respectively; relative risk, 1.18; 95% CI, 0.79–1.76)
  • The safety profile was similar between treatment groups, except there was a longer recovery of neutrophils and platelets with CPX-351 (35 vs 29 days and 37 vs 28 days, respectively) compared to the 7+3 regimen (Table 1)
    • No deaths were reported within 60 days post treatment

Table 1. Treatment-emergent adverse events

TEAE, treatment-emergent adverse event


(n = 59)

(n = 40)

TEAEs in ≥ 50% of patients in either group, %

Febrile neutropenia



Peripheral edema

















Serious TEAEs in ≥ 10% of patients in either group, %

Febrile neutropenia

Decreased ejection fraction








The authors demonstrated improved median OS with CPX-351 compared to 7+3 chemotherapy in patients with AML-MRC who achieved CR + CRi. The safety profile in this subgroup was consistent with the overall study population.1,2

  1. Lancet JE. et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018 Sep 10; 36(26): 2684–2692. DOI: 10.1200/JCO.2017.77.6112
  2. Ryan DH. et al. Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis. Biol Blood Marrow Transplant. 2020 March; 26(3): S9–S10. DOI: